TIANJIN, CHINA, November 26th, 2019, CanSino Biologics Inc. (“CanSinoBIO”, HK6185) signed a Memorandum on Reciprocal Developmental Programs with Tianjin Medical Products Administration (TMPA), in an effort to strengthen the regulator’s capacity and capabilities on routine surveillance inspections to vaccine manufacturers. This is the first ever in China that a local drug regulator and a vaccine manufacturer teamed up for the developmental purposes.

The two parties agreed to roll out a package of developmental programs centering on design and execution of practical agendas tailored for development of competent inspectors for routine surveillance inspections, using the vaccine manufacturing facilities, processes and systems that CanSinoBIO has in place in Binhai New Area of Tianjin. With the arrangement, TMPA will offer reciprocal program agendas to scale up CanSinoBIO’s capability in quality control and compliance. The two parties also agree to commit their respective resources and connections for development of other program agendas of mutual interests.

“CanSinoBIO has the world-class vaccine manufacturing facilities, processes and quality control systems that make it a perfect choice for us to work with for development of competent inspectors that play pivotal roles in controlling supplies of quality vaccines, and subsequently the public health security”, said Xudong Wang, Director of Tianjin Medical Products Administration.

“To ensure vaccine quality and thereon the public health security is the shared responsibility of vaccine manufacturers and industry regulators as well. The programs we have with TMPA will help strengthen our quality control and compliance capabilities in all processes and systems related to research and development, production, cold-chained distribution and delivery at the points of vaccination”, said Xuefeng Yu, CanSinoBIO’s Chairman and CEO.

A ceremony in evidence of the memorandum signature and the program opening was held on the afternoon of November 26, 2019. Present at the event were senior executives from CanSinoBIO, TMPA leaders and officials from the development zone.

About CanSino Biologics Inc.

Incorporated in 2009, CanSinoBIO (6185.HK) commits to research, development, production and commercialization of innovative vaccines for China and global public health. It possesses four integrated platform technologies including adenovirus-based vectors, conjugation, protein design and recombination and formulation. As of today, it has established a robust pipeline of 15 candidate vaccines covering 12 diseases, including a globally innovative Ebola virus disease vaccine approved for emergency use and stockpile in 2017.